|
Market Closed -
Nasdaq
01:30:00 22/08/2026 am IST
|
5-day change | 1st Jan Change | ||
| 207.77 USD | -0.12% |
|
-2.76% | +13.76% |
| 12/08 | UBS Adjusts Price Target on Axsome Therapeutics to $280 From $259, Keeps Buy Rating | MT |
| 12/08 | Mizuho Adjusts PT on Axsome Therapeutics to $316 From $306, Keeps Outperform Rating | MT |
Company Valuation: Axsome Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 1,424 | 3,349 | 3,766 | 4,100 | 9,207 | 10,883 | - | - |
| Change | - | 135.22% | 12.44% | 8.87% | 124.55% | 18.2% | - | - |
| Enterprise Value (EV) 1 | 1,387 | 3,243 | 3,558 | 3,966 | 9,072 | 10,727 | 10,448 | 9,984 |
| Change | - | 133.87% | 9.72% | 11.46% | 128.76% | 18.24% | -2.6% | -4.44% |
| P/E | -10.9x | -16.8x | -15.1x | -14.1x | -49.6x | -78x | 44.6x | 16.3x |
| PBR | 90.9x | 30.6x | 19.7x | 72.2x | 105x | 137x | 36.3x | 13.4x |
| PEG | - | -0.5x | -1x | -1x | 1.3x | 2.8x | -0x | 0x |
| Capitalization / Revenue | - | 66.9x | 13.9x | 10.6x | 14.4x | 11.2x | 6.97x | 4.86x |
| EV / Revenue | - | 64.8x | 13.1x | 10.3x | 14.2x | 11x | 6.69x | 4.46x |
| EV / EBITDA | -11.1x | -18.5x | -15.8x | -14.5x | -56.7x | -79.7x | 48.9x | 21x |
| EV / EBIT | -11.1x | -18x | -15.3x | -14.1x | -54.4x | -79.8x | 36x | 12.1x |
| EV / FCF | -12.8x | -27.7x | -24.4x | -30.8x | -96.6x | -68.5x | 26.7x | 13.7x |
| FCF Yield | -7.83% | -3.61% | -4.09% | -3.24% | -1.03% | -1.46% | 3.74% | 7.29% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -3.47 | -4.6 | -5.27 | -5.99 | -3.68 | -2.665 | 4.664 | 12.76 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | - | 50.04 | 270.6 | 385.7 | 638.5 | 971 | 1,562 | 2,239 |
| EBITDA 1 | -124.6 | -175.4 | -225 | -273.6 | -159.9 | -134.5 | 213.6 | 475.3 |
| EBIT 1 | -124.7 | -179.8 | -231.8 | -280.6 | -166.8 | -134.5 | 289.8 | 823.1 |
| Net income 1 | -130.4 | -187.1 | -239.2 | -287.2 | -183.2 | -139.6 | 258.7 | 721 |
| Net Debt 1 | -37.38 | -106.6 | -208.1 | -134.6 | -135.2 | -156.5 | -435.3 | -898.9 |
| Reference price 2 | 37.78 | 77.13 | 79.59 | 84.61 | 182.64 | 207.77 | 207.77 | 207.77 |
| Nbr of stocks (in thousands) | 37,692 | 43,426 | 47,320 | 48,462 | 50,413 | 52,381 | - | - |
| Announcement Date | 01/03/22 | 27/02/23 | 20/02/24 | 18/02/25 | 23/02/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -77.97x | 11.05x | -79.73x | -.--% | 1.09TCr | |
| 19.31x | 4.52x | 10.64x | 0.47% | 8.33TCr | |
| -16.91x | 25.77x | -16.64x | -.--% | 5.79TCr | |
| 19.86x | 4.25x | 13.12x | 2.5% | 5.78TCr | |
| 37.73x | 12.91x | 24.53x | -.--% | 5.17TCr | |
| 22.2x | 4.9x | 14.02x | 0.66% | 4.93TCr | |
| 38.52x | 3.54x | 13.49x | -.--% | 3.2TCr | |
| 57.04x | 3.65x | 28.27x | -.--% | 2.59TCr | |
| 75.75x | 7.38x | 49.38x | -.--% | 2.27TCr | |
| 24.11x | 5.18x | 13.48x | -.--% | 1.69TCr | |
| Average | 19.96x | 8.31x | 7.06x | 0.36% | 4.09TCr | |
| Weighted average by Cap. | 21.58x | 8.83x | 10.50x | 0.53% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- AXSM Stock
- Valuation Axsome Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
